# Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

> **NCT06797518** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (estimated)

## Conditions studied

- Glomerulonephritis, IGA
- Immunoglobulin A Nephropathy

## Interventions

- **DRUG:** Iptacopan

## Key facts

- **NCT ID:** NCT06797518
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-21
- **Primary completion:** 2027-11-27
- **Final completion:** 2027-11-27
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797518, "Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06797518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*